A Randomized Non-Comparative Multicenter Phase II Study of Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2013
At a glance
- Drugs Everolimus (Primary) ; Sorafenib (Primary) ; Sunitinib
- Indications Renal cancer
- Focus Therapeutic Use
- 05 Apr 2013 Actual initiation date Jul 2012 added as reported by ClinicalTrials.gov.
- 05 Apr 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 15 Jun 2012 New trial record